Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

One To Watch: Chi-Med Approaches Inflection Points

Executive Summary

Hutchison China MediTech, or Chi-Med, will report pivotal or proof of concept data for savolitinib, fruquintinib and two other tyrosine kinase inhibitor candidates by Q1 2017. Having built a global cancer and inflammation R&D pipeline on the back of what started out 16 years ago as a domestic commercial botanicals business based in China, Chi-Med is now one to watch.

You may also be interested in...



PROFILE: Chi-Med Lays Out Broad Strategy As Fruquintinib Advances

Newly NASDAQ-listed Chi-Med has completed enrollment in a Phase III trial with fruquintinib in colorectal cancer patients in China, a potentially large market for its lead drug, and is pushing ahead with US development plans for the VEGFR inhibitor. The Hong Kong-based firm also sees attractive possibilities for combination use in earlier lines of therapy and in additional indications and mature markets, its CEO says.

Gaming Whiz Brings AI Smarts To Drug Discovery

GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.

The Top 10 Best-Selling Drugs of 2019

INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market. 

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel